Stock Events

Stock Events

BioXcel Therapeutics 

0
154
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q1 2026
Q2 2026
Next
-0.87
-0.71
-0.54
-0.38
Expected EPS
-0.868802
Actual EPS
N/A

Financials

-10,739.62%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
558,768.22Revenue
-60.01MNet Income

Analyst Ratings

8.35Average Price Target
The highest estimate is 12.90.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BX2.MU. It's not an investment recommendation.
Apple
20
AAPL
Microsoft
19
MSFT
NVIDIA
18
NVDA
Palantir Technologies
18
PLTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap7.95B
Alkermes develops therapies for central nervous system (CNS) diseases, including schizophrenia and depression, overlapping with BioXcel's focus areas.
Acadia Pharmaceuticals
ACAD
Mkt Cap5.02B
ACADIA Pharmaceuticals specializes in CNS disorders, particularly Parkinson’s disease psychosis, competing in the neuropsychiatric space.
Insmed
INSM
Mkt Cap25.89B
Insmed incorporates novel approaches to treat serious and rare diseases, including neurological disorders, potentially competing with BioXcel's innovative approaches.
BridgeBio Pharma
BBIO
Mkt Cap14.97B
BridgeBio Pharma targets genetic diseases and cancers with a precision medicine approach, indirectly competing in the innovation space for treatments.
Protagonist Therapeutics
PTGX
Mkt Cap9.34B
Protagonist Therapeutics is involved in developing peptide-based treatments that could compete with BioXcel's therapies in various indications.
Axsome Therapeutics
AXSM
Mkt Cap10.42B
Axsome Therapeutics focuses on developing treatments for central nervous system disorders, including depression and migraine, competing in BioXcel's market.
Voyager Therapeutics
VYGR
Mkt Cap218.13M
Voyager Therapeutics specializes in severe neurological diseases by developing gene therapies, offering a different approach but competing in the same therapeutic area.

About

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Show more...
CEO
Vimal D. Mehta
Employees
29
Country
United States
ISIN
US09075P1057

Listings

F
DE
BX20.F
STU
DE
BX20.STU
MU
DE
BX2.MU
MU
DE
BX20.MU

0 Comments

Share your thoughts

FAQ

What is BioXcel Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange BioXcel Therapeutics stocks are traded under the ticker BX2.MU.
When is the next BioXcel Therapeutics earnings date?▼
BioXcel Therapeutics is going to release the next earnings report on November 18, 2026.
What is BioXcel Therapeutics revenue for the last year?▼
BioXcel Therapeutics revenue for the last year amounts to 558,768.22 EUR.
What is BioXcel Therapeutics net income for the last year?▼
BX2.MU net income for the last year is -60.01M EUR.
How many employees does BioXcel Therapeutics have?▼
As of September 04, 2026, the company has 29 employees.
In which sector is BioXcel Therapeutics located?▼
BioXcel Therapeutics operates in the Health & Wellness sector.
When did BioXcel Therapeutics complete a stock split?▼
The last stock split for BioXcel Therapeutics was on February 10, 2025 with a ratio of 1:16.
Where is BioXcel Therapeutics headquartered?▼
BioXcel Therapeutics is headquartered in NEW HAVEN, United States.